Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

This is a randomized double-blind/placebo study evaluate the efficacy of ASN002 in subjects with moderate to severe atopic dermatitis (AD).

Study Overview

• Status: Completed
• Conditions: Atopic Dermatitis
• Intervention / Treatment: Drug: ASN002; Drug: Placebo Oral Tablet

Detailed Description

This is a placebo controlled study where subjects with moderate to severe atopic dermatitis will be randomized (1:1:1:1) to receive ASN002 at 40 mg, 60 mg, or 80 mg, or placebo once daily for 12 weeks. Eligible subjects will get the opportunity to enroll in the 24 month open-label extension study (OLE). There will be a 4-week follow up period for subjects not participating in the OLE study. This study will also characterize the pharmacokinetics and pharmacodynamics of ASN002 through blood sampling and three or four biopsies from subjects who consent.

• Study Type: Interventional
• Enrollment (Actual): 244
• Phase: Phase 2

Contacts and Locations

Study Locations

• Canada
  • Calgary, Canada, T3A2N1
    • Institute of Skin Advancement Medical, Surgical, Costmetic & Laser Dermatology
  • Montreal, Canada, H2K4L5
    • Innovaderm Research, Inc.
  • Ottawa, Canada, K2C3N2
    • Ontario Inc.
  • Richmond Hill, Canada, L4C9M7
    • York Regional Dermatology
  • Saint John's, Canada, A1C2H5
    • NewLab Clinical Research, Inc.
  • Toronto, Canada, M5A3R6
    • AvantDerm
  • Winnipeg, Canada, ABR3M3Z4
    • SkinWise Dermatology
• Germany
  • Bad Bentheim, Germany
    • Fachklinik Bad Bentheim
  • Berlin, Germany
    • Charité - Universitätsmedizin Berlin
  • Bonn, Germany
    • Universitätsklinikum Bonn AöR
  • Dresden, Germany
    • Universitätsklinikum Dresden
  • Frankfurt, Germany
    • Universitatsklinikum Frankfurt
  • Gera, Germany
    • SRH Wald-Klinikum Gera GmbH
  • Hamburg, Germany
    • MensingDerma research GmbH
  • Hannover, Germany
    • Medizinische Hochschule Hannover
  • Lubeck, Germany
    • Universitätsklinikum Schleswig-Holstein
  • Münster, Germany
    • Universitätshautklinik Münster
• United States
  • Alabama
    • Anniston, Alabama, United States, 36207
      • Pinnacle Research Group, LLC
    • Birmingham, Alabama, United States, 35205
      • Total Skin and Dermatology Center, PC.
  • California
    • Fremont, California, United States, 94538
      • Center For Dermatology Clinical Research, Inc.
    • Los Angeles, California, United States, 90045
      • Dermatology Research Associates
    • Los Angeles, California, United States, 89148
      • L.A. Universal Research Center, Inc.
  • Florida
    • Doral, Florida, United States, 33122
      • Revival Research
    • Fort Myers, Florida, United States, 33912
      • Clinical Physiology Associates
    • Ormond Beach, Florida, United States, 32174
      • Leavitt Medical Associates of Florida
    • Tampa, Florida, United States, 33625
      • Dermatology Consulting Services
    • Tampa, Florida, United States, 33625
      • Forward Clinical Trials
  • Indiana
    • Indianapolis, Indiana, United States, 46256
      • Dawes Fretzin Clinical Research Group
    • Plainfield, Indiana, United States, 46168
      • The Indiana Clinical Trials Center
    • Plainfield, Indiana, United States, 46168
      • Dermatology Center of Indiana, PC
  • Kentucky
    • Lexington, Kentucky, United States, 40509
      • Central Kentucky Research Associates, LLC
    • Louisville, Kentucky, United States, 40241
      • Dermatology Specialists Research
  • New Hampshire
    • Portsmouth, New Hampshire, United States, 03801
      • ActivMed Practices and Research, Inc.
  • New York
    • Corning, New York, United States, 14830
      • Corning Center for Clinical Research
    • New York, New York, United States, 10029
      • Mt. Sinai Hospital
  • North Carolina
    • Raleigh, North Carolina, United States, 27612
      • Wake Research Associates, LLC
  • Ohio
    • Bexley, Ohio, United States, 43209
      • Dermatologists of Greater Colombus
    • Fairborn, Ohio, United States, 45324
      • Wright State Physicians
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73118
      • Unity Clinical Research
    • Tulsa, Oklahoma, United States, 74136
      • Vital Prospects Clinical Research Institute
  • Pennsylvania
    • Hazleton, Pennsylvania, United States, 18201
      • DermDox Centers for Dermatology
  • South Carolina
    • Greer, South Carolina, United States, 29651
      • Synexus
  • Texas
    • Dallas, Texas, United States, 75320
      • Dermatology Treatment and Research Center
    • Fort Worth, Texas, United States, 76244
      • Innovate Research, LLC
    • Houston, Texas, United States, 77056
      • The Center for Skin Research
    • San Antonio, Texas, United States, 78213
      • Progressive Clinical Research
  • Virginia
    • Norfolk, Virginia, United States, 23502
      • Virginia Clinical Research, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Written informed consent obtained prior to any study-related procedure being performed;

  • Male or female, 18≤ years and ≤75 years of age with chronic AD for at least 6 months.
  • At least 10% body surface area (BSA) of AD involvement at the baseline visits
  • Has a body mass index (BMI) ≤35 kg/m2
  • History of inadequate response to topical corticosteroids or calcineurin inhibitors as treatment for AD within 1 year before the screening visit.
  • Willing to apply only a basic bland emollient once or twice-daily for at least 7 days before the baseline visit.
  • Willing to comply with discontinuation of certain treatments for AD, as directed by the Investigator.
  • Willing to use medically effective methods of birth control
  • Females of reproductive potential must have a negative serum pregnancy test at screening and negative urine pregnancy test at Day 1..
  • Willing and able to comply with clinic visits and study-related procedures

Exclusion Criteria:

• Clinically infected atopic dermatitis.

  • Presence of any of the following laboratory abnormalities at the screening visit: Hemoglobin < 11 g/dL, White blood cell (WBC) < 3.0 x 103 /μL, Platelet count < 125 x 103 /μL, Neutrophils < < 2.50 x 103 /μL, Lymphocytes ≤ 1.2 x 103 /μL, Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 1.5 x the upper limit of normal (ULN),Total bilirubin > ULN (except for elevated indirect bilirubin secondary to Gilbert's syndrome), Creatinine > ULN
  • A serious uncontrolled condition including hypertension, history of tuberculosis, hepatitis B or C infection, immune deficiency, heart disease, heart conduction disorder, diverticulitis, diabetes, reflux disease requiring protocol pump inhibitor therapy, malabsorption syndrome, or cancer.
  • Any condition requiring the use of anticoagulants.
  • History of hypertrophic scarring or keloid formation in scars or suture sites.
  • Any medical or psychiatric condition which, in the opinion of the investigator or the sponsor's medical monitor, would place the patient at risk, interfere with participation in the study, or interfere with the interpretation of study results
  • Pregnant or breast-feeding women
  • Known hypersensitivity to ASN002 or its excipients;
  • Prior treatment with SYK or JAK inhibitors for which the subject received no clinical benefit, or the subject relapsed whilst on therapy.
  • Has received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.
  • Planned major surgical procedure during the length of the patient's participation in this study
  • There will be a waiting period of 4 weeks before receiving the first does for anyone who has used oral or intravenous treatments (other than biologics) that could affect atopic dermatitis, received a non-biological investigational product or device, excessive sun exposure, is planning a trip to a sunny climate, or has used tanning booths, or received or plans to receive a live attenuated vaccine one four weeks after the last day of taking the drug.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: ASN002 40 mg; 40 mg ASN002	Drug: ASN002; Daily dose of ASN002 for 12 weeks
Experimental: ASN002 80 mg; 80 mg ASN002	Drug: ASN002; Daily dose of ASN002 for 12 weeks
Experimental: ASN002 60 mg; 60 mg ASN002	Drug: ASN002; Daily dose of ASN002 for 12 weeks
Experimental: Placebo Oral Tablet; Matching placebo for ASN002 doses	Drug: Placebo Oral Tablet; Placebo of ASN002 for 12 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change From Baseline in Eczema Area and Severity Index (EASI) at Week 12	The Eczema Area and Severity Index (EASI) is a composite score ranging from 0 to 72, the higher the value the worse the disease, that takes into account the degree of erythema, induration/infiltration (papules), excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percentage of BSA involved for each body region and for the proportion of the body region to the whole body.	Week 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent of Participant With at Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI75)	Percent of participants with at least a 75% reduction from baseline in EASI (EASI75) at Week 12	Week 12
Change From Baseline in 5-D Pruritus (Itching) Scale	The 5-D Pruritus Scale is a 1-page, 5-question, validated questionnaire used in clinical trials to assess 5 dimensions of background itch: degree, duration, direction, disability, and distribution. Each question corresponds to 1 of the 5 dimensions of itch; subjects rated their symptoms over the preceding 2-week period as "present" or on a 1 to 5 scale, with 5 being the most affected. The total score of 5-D pruritus is a sum of the 5 scores to provide a total score range from 5 (best) to 25 (worst).	Week 12
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD)	In the SCORAD grading system, six items (erythema, edema/papulation, oozing/crusts, excoriation, lichenification, and dryness) evaluate the Atopic Dermatitis severity. The overall body surface area affected by atopic dermatitis was evaluated (from 0% to 100%) and included in the SCORAD scores. Loss of sleep and pruritus were evaluated by subjects on a visual analog scale (0-10) and were based on the average of the last three days/nights. The sum of these measures represented the SCORAD, which could range from 0 to 103. The higher the score the more severe the disease.	Week 12
Percentage of Participants With a Response of Investigator's Global Assessment (IGA) 0 or 1	The IGA is a global assessment of the current state of the disease. It is a 5-point (0-4) morphological assessment of overall disease severity. The 0 is the least severe and 4 is the most severe.	Week 12
Change From Baseline in Patient-Oriented Eczema Measure (POEM)	The Patient-Oriented Eczema Measure (POEM) is a self-assessment of disease severity by the subject. The POEM has a maximum value of 28 based on the subject's response to seven questions scored from 0 to 4. The higher the value the more severe the disease is.	Week 12
Change From Baseline in Dermatology Life Quality Index (DLQI)	Dermatology Life Quality Index Questionnaire (DLQI) is a simple 10-question validated questionnaire that has been used in more than 40 different skin conditions. The DLQI total score is defined as the sum of the 10 item scales, ranging from 0 to 30. The higher the value, the more severe the disease is.	Week 12
Change From Baseline in Body Surface Area (BSA)	The overall body surface area (BSA) affected by atopic dermatitis is evaluated (from 0% to 100%).	Week 12

Collaborators and Investigators

• Sponsor: Asana BioSciences
• Investigators: Study Director: David Zammit, Ph.D., Asana BioSciences

Study record dates

Study Major Dates

• Study Start (Actual): July 5, 2018
• Primary Completion (Actual): July 22, 2019
• Study Completion (Actual): August 14, 2019

Study Registration Dates

• First Submitted: April 19, 2018
• First Submitted That Met QC Criteria: May 9, 2018
• First Posted (Actual): May 22, 2018

Study Record Updates

• Last Update Posted (Actual): July 3, 2023
• Last Update Submitted That Met QC Criteria: June 28, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Keywords: eczema
• Additional Relevant MeSH Terms: Skin Diseases; Immune System Diseases; Hypersensitivity, Immediate; Genetic Diseases, Inborn; Skin Diseases, Genetic; Hypersensitivity; Skin Diseases, Eczematous; Dermatitis; Eczema; Dermatitis, Atopic
• Other Study ID Numbers: ASN002AD-201

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No